MetaCap

Century Therapeutics (IPSC) vs Scribe Therapeutics (SCTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Scribe Therapeutics is the larger company by market cap ($228.6 million vs $211.6 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IPSC-44.26%SCTX-36.37%
+103%+26%-51%
Jul 27, 20261 yearNov 20, 2026
IPSC-42.33%SCTX-38.04%
+81%+16%-48%
Jul 27, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IPSC versus SCTX key metrics
MetricIPSCSCTX
Share price$1.17$12.07
Market cap$211.56M$228.58M
1-day change-11.74%-8.70%
YTD return+17.09%—
1-year return+137.76%—
5-year return-93.23%—
EPS (TTM)$-0.64$-6.35
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$109.16M—
Revenue growth (YoY)+1556.76%—
Net income (latest FY)$-9.58M—
Operating margin-15.82%—
Net margin-8.78%—
52-week high$3.04$39.60
52-week low$0.48$12.00
Distance from 52-week high-61.68%-69.52%
Analyst consensusbuystrong_buy
Avg. price target upside+307.73%+372.25%
Average volume759.69K403.27K
Shares outstanding181.60M18.94M
Employees7877
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Century Therapeutics

IPSC stock →

Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 78 employees

About Scribe Therapeutics

SCTX stock →

Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 77 employees

IPSC vs SCTX FAQ

Which is bigger, Century Therapeutics or Scribe Therapeutics?

Scribe Therapeutics (SCTX) is larger, with a market capitalization of $228.58M compared with $211.56M for Century Therapeutics (IPSC).

Are Century Therapeutics and Scribe Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons